Remove 2019 Remove Immunity Remove Vaccines
article thumbnail

Five Things For Pharmacists To Know About Measles in 2025

ID Stewardship

Although I have practiced in the area of infectious diseases pharmacy for quite a while now, measles has not been of much clinical relevance to me beyond MMR for routine vaccination. Vaccination is the best way to prevent measles This is an obvious one, but necessary to state right out the gate. MMR is given in 2 doses.

Vaccines 119
article thumbnail

Should People With Immune Problems Get Third Vaccine Doses?

NY Times

France is handing out third shots of the two-dose vaccines to cancer patients and others with immune system impairments. In the United States, patients like these are on their own.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

BioNTech takes its first cancer vaccine into phase 2

pharmaphorum

It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on cancer vaccines, before being catapulted onto the world-stage with its COVID-19 shot. The post BioNTech takes its first cancer vaccine into phase 2 appeared first on.

Vaccines 145
article thumbnail

Vaccines Won’t Protect Millions of Patients With Weakened Immune Systems

NY Times

Many cannot produce enough infection-fighting cells to fend off the coronavirus. But researchers are testing one therapy that may help: monoclonal antibodies.

Immunity 130
article thumbnail

Johnson & Johnson Will Test its Vaccine in Infants

NY Times

The company’s coming trials will also involve pregnant women and people whose immune systems are compromised.

Immunity 144
article thumbnail

F.D.A. Clears Moderna's Covid Vaccine

NY Times

The Food and Drug Administration authorized a second coronavirus vaccine for emergency use, clearing the way for millions more Americans to be immunized next week.

Vaccines 105
article thumbnail

STAT+: Foundation charges cancer patients $83,000 for unproven but promising experimental drug

STAT

Still, when doctors told her last year that the cancer was growing despite two operations, radiation therapy, and a fifth regimen of chemotherapy, the retired business-meeting facilitator decided to do something unorthodox: spend $83,000 out of pocket on an unproven experimental cancer vaccine.

Vaccines 246